Cytosorbents Corp (CTSO)
NASDAQ:CTSO
Want to see CTSO full AI Analyst Report?
CTSO Stock Chart & Stats
$0.70
-$0.05(-4.55%)
At close: 4:00 PM EST
$0.70
-$0.05(-4.55%)
Day’s Range― - ―
52-Week Range$0.37 - $1.39
Previous CloseN/A
Volume86.19K
Average Volume (3M)134.35K
Market Cap
$24.37M
Enterprise Value$44.98M
Total Cash (Recent Filing)$4.81M
Total Debt (Recent Filing)$18.96M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 04, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding62,794,746
10 Day Avg. Volume163,660
30 Day Avg. Volume134,354
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)6.74
Price to Sales (P/S)1.07
P/FCF Ratio-3.17
Enterprise Value/Market Cap1.85
Enterprise Value/Revenue1.21
Enterprise Value/Gross Profit1.70
Enterprise Value/Ebitda-6.49
Forecast
1Y Price Target
$0.75Price Target Upside7.14% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$39.28M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 70% indicate durable product-level economics for CytoSorb cartridges. High unit margins give the business leverage as volume scales, enabling margin expansion or cushioning against pricing pressure and helping support a path to profitability as fixed costs are reduced.
Recurring Consumable Model And Installed BaseA large global installed base and razor/razor-blade consumable model create recurring procedure-driven revenue. Each treatment uses a disposable cartridge, making revenue more predictable per procedure and supporting long-term adoption, cross-sell and durable revenue tail from hospitals and ICUs worldwide.
Cost Controls With Clear Breakeven TargetDemonstrable expense reductions and improving adjusted profitability show management can shrink losses. A stated target of operating cash-flow breakeven (H2 2026) provides a concrete operational milestone; if achieved, it materially reduces funding dependence and supports sustainable operations.
Bears Say
High Financial LeverageVery elevated leverage drastically narrows financial flexibility and raises refinancing or covenant risk. With equity compressed, the company faces increased probability of dilution or restrictive credit terms, which can impede investment in commercialization and regulatory studies needed to grow revenue.
Persistent Negative Cash FlowSustained negative operating and free cash flow indicates the core business still consumes cash despite improvement. Ongoing burn forces reliance on external financing or asset sales, increasing dilution risk and constraining the company's ability to fund clinical/regulatory programs and international expansion.
Regulatory Delay And Added Study RequirementsAdditional FDA-requested mechanistic studies and RWE extend time-to-market and raise development costs for the U.S. DrugSorb‑ATR opportunity. This delays access to a sizable TAM, compresses near-term revenue potential, and increases near-term funding needs amid already limited liquidity.
Cytosorbents News
CTSO FAQ
What was Cytosorbents Corp’s price range in the past 12 months?
Cytosorbents Corp lowest stock price was $0.37 and its highest was $1.39 in the past 12 months.
What is Cytosorbents Corp’s market cap?
Cytosorbents Corp’s market cap is $24.37M.
When is Cytosorbents Corp’s upcoming earnings report date?
Cytosorbents Corp’s upcoming earnings report date is Aug 04, 2026 which is in 53 days.
How were Cytosorbents Corp’s earnings last quarter?
Cytosorbents Corp released its earnings results on May 13, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.03.
Is Cytosorbents Corp overvalued?
According to Wall Street analysts Cytosorbents Corp’s price is currently Undervalued.
Does Cytosorbents Corp pay dividends?
Cytosorbents Corp does not currently pay dividends.
What is Cytosorbents Corp’s EPS estimate?
Cytosorbents Corp’s EPS estimate is -0.04.
How many shares outstanding does Cytosorbents Corp have?
Cytosorbents Corp has 62,794,746 shares outstanding.
What happened to Cytosorbents Corp’s price movement after its last earnings report?
Cytosorbents Corp reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -5.088%.
Which hedge fund is a major shareholder of Cytosorbents Corp?
Currently, no hedge funds are holding shares in CTSO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cytosorbents Corp
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
CTSO Company Deck
CTSO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced operational and commercial progress against near‑term financial and regulatory challenges. Positives include modest top-line growth, strong international direct momentum (+13% YoY), healthy gross margins (69%), improved adjusted profitability metrics, strengthening clinical evidence (STAR-T showing >50% reduction in severe bleeding), and clearer regulatory direction with two FDA breakthrough designations. Main negatives are the widened GAAP net loss driven by FX, lower cash balance (~$6.4M), a delayed de novo submission requiring additional mechanistic studies and resources (likely pushing approval into late 2026/early 2027), Germany market softness, and a $0.5M order disruption tied to geopolitical events. Overall, management is executing cost reductions and targeting operating cash flow breakeven in H2 2026, and the call conveyed cautious optimism despite the identified risks.View all CTSO earnings summariesCTSO Stock 12 Month Forecast
Average Price Target
$0.75
▲(7.14% Upside)
Technical Analysis
Electrocore
―
TELA Bio
―
Spectral AI
―
Icecure Medical
―
Baird Medical Investment Holdings
―
Ownership Overview
5.93% Insiders
6.65% Mutual Funds
14.73% Other Institutional Investors
69.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---